Related Experiment Video
Updated: Aug 18, 2026

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
Nitazoxanide: a new thiazolide antiparasitic agent
LeAnne M Fox1, Louis D Saravolatz
1Division of Infectious Diseases, Children's Hospital, Boston, MA, USA. lfox@bu.edu
Abstract:
Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects. At present, there are no documented drug-drug interactions. Nitazoxanide has been licensed for the treatment of Giardia intestinalis-induced diarrhea in patients >or=1 year of age and Cryptosporidum-induced diarrhea in children aged 1-11 years. At present, it is pending licensure for treatment of infection due to Cryptosporidium species in adults and for use in treating immunocompromised hosts. It represents an important addition to the antiparasitic arsenal.
Related Concept Videos
Anthelminthic Agents
Antiprotozoal Agents
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Antiviral Nucleoside Inhibitors
Antihypertensive Drugs: Thiazide-Class Diuretics
Antifungal Agents
